21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR Part 870 Subpart C (May 22, 2025)
This content is from the eCFR and is authoritative but unofficial.
45 FR 7907, Feb. 5, 1980, unless otherwise noted.
Title 21—Food and Drugs
Chapter I—Food and Drug Administration, Department of Health and Human Services
Subchapter H—Medical Devices
Part 870—Cardiovascular Devices
Authority: 21 U.S.C. 351,360,360c,360e,360j,360l, 371.
Source: Subpart C Cardiovascular Monitoring Devices
§ 870.2050 Biopotential amplifier and signal conditioner.
§ 870.2060 Transducer signal amplifier and conditioner.
§ 870.2100 Cardiovascular blood flowmeter.
§ 870.2120 Extravascular blood flow probe.
§ 870.2200 Adjunctive cardiovascular status indicator.
§ 870.2210 Adjunctive predictive cardiovascular indicator.
§ 870.2220 Adjunctive hemodynamic indicator with decision point.
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
§ 870.2310 Apex cardiograph (vibrocardiograph).
§ 870.2320 Ballistocardiograph.
§ 870.2330 Echocardiograph.
§ 870.2340 Electrocardiograph.
§ 870.2345 Electrocardiograph software for over-the-counter use.
§ 870.2350 Electrocardiograph lead switching adaptor.
§ 870.2360 Electrocardiograph electrode.
§ 870.2370 Electrocardiograph surface electrode tester.
§ 870.2390 Phonocardiograph.
§ 870.2400 Vectorcardiograph.
§ 870.2450 Medical cathode-ray tube display.
§ 870.2600 Signal isolation system.
§ 870.2620 Line isolation monitor.
§ 870.2640 Portable leakage current alarm.
§ 870.2675 Oscillometer.
§ 870.2700 Oximeter.
§ 870.2710 Ear oximeter.
§ 870.2750 Impedance phlebograph.
§ 870.2770 Impedance plethysmograph.
§ 870.2780 § 870.2785 rate, and/or respiratory rate.
21 CFR Part 870 Subpart C (May 22, 2025) (enhanced display) Hydraulic, pneumatic, or photoelectric plethysmographs.
Software for optical camera-based measurement of pulse rate, heart rate, breathing
page 1 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
§ 870.2786 Hardware and software for optical camera-based measurement of pulse rate, heart
rate, breathing rate, and/or respiratory rate.
§ 870.2790 Photoplethysmograph analysis software for over-the-counter use.
§ 870.2800 Medical magnetic tape recorder.
§ 870.2810 Paper chart recorder.
§ 870.2840 Apex cardiographic transducer.
§ 870.2850 Extravascular blood pressure transducer.
§ 870.2855 Implantable Intra-aneurysm Pressure Measurement System.
§ 870.2860 Heart sound transducer.
§ 870.2870 Catheter tip pressure transducer.
§ 870.2880 Ultrasonic transducer.
§ 870.2890 Vessel occlusion transducer.
§ 870.2900 Patient transducer and electrode cable (including connector).
§ 870.2910 Radiofrequency physiological signal transmitter and receiver.
§ 870.2920 Telephone electrocardiograph transmitter and receiver.
21 CFR Part 870 Subpart C (May 22, 2025)
Editorial Note: Nomenclature changes to part 870 appear at73 FR 35341, June 23, 2008.
Subpart C—Cardiovascular Monitoring Devices
§ 870.2050 Biopotential amplifier and signal conditioner.
(a) Identification. A biopotential amplifier and signal conditioner is a device used to amplify or condition an
electrical signal of biologic origin.
(b) Classification. Class II (performance standards).
§ 870.2060 Transducer signal amplifier and conditioner.
(a) Identification. A transducer signal amplifier and conditioner is a device used to provide the excitation
energy for the transducer and to amplify or condition the signal emitted by the transducer.
(b) Classification. Class II (performance standards).
§ 870.2100 Cardiovascular blood flowmeter.
(a) Identification. A cardiovascular blood flowmeter is a device that is connected to a flow transducer that
energizes the transducer and processes and displays the blood flow signal.
(b) Classification. Class II (performance standards).
§ 870.2120 Extravascular blood flow probe.
(a) Identification. An extravascular blood flow probe is an extravascular ultrasonic or electromagnetic probe
used in conjunction with a blood flowmeter to measure blood flow in a chamber or vessel.
(b) Classification. Class II (performance standards).
21 CFR 870.2120(b) (enhanced display) page 2 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2200
§ 870.2200 Adjunctive cardiovascular status indicator.
(a) Identification. The adjunctive cardiovascular status indicator is a prescription device based on sensor
technology for the measurement of a physical parameter(s). This device is intended for adjunctive use
with other physical vital sign parameters and patient information and is not intended to independently
direct therapy.
(b) Classification. Class II (special controls). The special controls for this device are:
(1) (2) (3) (4) (5) Software description, verification, and validation based on comprehensive hazard analysis must be
provided, including:
(i) Full characterization of technical parameters of the software, including any proprietary
algorithm(s);
(ii) Description of the expected impact of all applicable sensor acquisition hardware characteristics
on performance and any associated hardware specifications;
(iii) Specification of acceptable incoming sensor data quality control measures; and
(iv) Mitigation of impact of user error or failure of any subsystem components (signal detection and
analysis, data display, and storage) on accuracy of patient reports.
Scientific justification for the validity of the status indicator algorithm(s) must be provided.
Verification of algorithm calculations and validation testing of the algorithm using a data set
separate from the training data must demonstrate the validity of modeling.
Usability assessment must be provided to demonstrate that risk of misinterpretation of the status
indicator is appropriately mitigated.
Clinical data must be provided in support of the intended use and include the following:
(i) Output measure(s) must be compared to an acceptable reference method to demonstrate that
the output measure(s) represent(s) the predictive measure(s) that the device provides in an
accurate and reproducible manner;
(ii) The data set must be representative of the intended use population for the device. Any
selection criteria or limitations of the samples must be fully described and justified;
(iii) Agreement of the measure(s) with the reference measure(s) must be assessed across the full
measurement range; and
(iv) Data must be provided within the clinical validation study or using equivalent datasets to
demonstrate the consistency of the output and be representative of the range of data sources
and data quality likely to be encountered in the intended use population and relevant use
conditions in the intended use environment.
Labeling must include the following:
(i) The type of sensor data used, including specification of compatible sensors for data
acquisition;
(ii) A description of what the device measures and outputs to the user;
(iii) Warnings identifying sensor reading acquisition factors that may impact measurement results;
21 CFR 870.2200(b)(5)(iii) (enhanced display) page 3 of 15
(b) 21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2200(b)(5)(iv)
(iv) Guidance for interpretation of the measurements, including warning(s) specifying adjunctive
use of the measurements;
(v) Key assumptions made in the calculation and determination of measurements;
(vi) The measurement performance of the device for all presented parameters, with appropriate
confidence intervals, and the supporting evidence for this performance; and
(vii) A detailed description of the patients studied in the clinical validation (e.g., age, gender, race/
ethnicity, clinical stability) as well as procedural details of the clinical study.
[82 FR 35067, July 28, 2017]
§ 870.2210 Adjunctive predictive cardiovascular indicator.
(a) Identification. The adjunctive predictive cardiovascular indicator is a prescription device that uses
software algorithms to analyze cardiovascular vital signs and predict future cardiovascular status or
events. This device is intended for adjunctive use with other physical vital sign parameters and patient
information and is not intended to independently direct therapy.
Classification. Class II (special controls). The special controls for this device are:
(1) A software description and the results of verification and validation testing based on a
comprehensive hazard analysis and risk assessment must be provided, including:
(i) A full characterization of the software technical parameters, including algorithms;
(ii) A description of the expected impact of all applicable sensor acquisition hardware
characteristics and associated hardware specifications;
(iii) A description of sensor data quality control measures;
(iv) A description of all mitigations for user error or failure of any subsystem components (including
signal detection, signal analysis, data display, and storage) on output accuracy;
(v) A description of the expected time to patient status or clinical event for all expected outputs,
accounting for differences in patient condition and environment; and
(vi) The sensitivity, specificity, positive predictive value, and negative predictive value in both
percentage and number form.
A scientific justification for the validity of the predictive cardiovascular indicator algorithm(s) must
be provided. This justification must include verification of the algorithm calculations and validation
using an independent data set.
A human factors and usability engineering assessment must be provided that evaluates the risk of
misinterpretation of device output.
A clinical data assessment must be provided. This assessment must fulfill the following:
(i) The assessment must include a summary of the clinical data used, including source, patient
demographics, and any techniques used for annotating and separating the data.
(ii) The clinical data must be representative of the intended use population for the device. Any
selection criteria or sample limitations must be fully described and justified.
(2) (3) (4) 21 CFR 870.2210(b)(4)(ii) (enhanced display) page 4 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2210(b)(4)(iii)
(iii) The assessment must demonstrate output consistency using the expected range of data
sources and data quality encountered in the intended use population and environment.
(iv) The assessment must evaluate how the device output correlates with the predicted event or
status.
(5) Labeling must include:
(i) A description of what the device measures and outputs to the user;
(ii) Warnings identifying sensor acquisition factors that may impact measurement results;
(iii) Guidance for interpretation of the measurements, including a statement that the output is
adjunctive to other physical vital sign parameters and patient information;
(iv) A specific time or a range of times before the predicted patient status or clinical event occurs,
accounting for differences in patient condition and environment;
(v) Key assumptions made during calculation of the output;
(vi) The type(s) of sensor data used, including specification of compatible sensors for data
acquisition;
(vii) The expected performance of the device for all intended use populations and environments;
and
(viii) Relevant characteristics of the patients studied in the clinical validation (including age, gender,
race or ethnicity, and patient condition) and a summary of validation results.
[87 FR 8191, Feb. 14, 2022]
§ 870.2220 Adjunctive hemodynamic indicator with decision point.
Identification. An adjunctive hemodynamic indicator with decision point is a device that identifies and
monitors hemodynamic condition(s) of interest and provides notifications at a clinically meaningful
decision point. This device is intended to be used adjunctively along with other monitoring and patient
information.
Classification. Class II (special controls). The special controls for this device are:
(1) Software description, verification, and validation based on comprehensive hazard analysis and risk
assessment must be provided, including:
(i) Full characterization of technical parameters of the software, including algorithm(s);
(ii) Description of the expected impact of all applicable sensor acquisition hardware characteristics
on performance and any associated hardware specifications;
(iii) Specification of acceptable incoming sensor data quality control measures;
(iv) Mitigation of impact of user error or failure of any subsystem components (signal detection and
analysis, data display, and storage) on output accuracy; and
(v) The sensitivity, specificity, positive predictive value, and negative predictive value in both
percentage and number form for clinically meaningful pre-specified time windows consistent
with the device output.
21 CFR 870.2220(b)(1)(v) (enhanced display) page 5 of 15
(a) (b) 
(2) (3) (4) 21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2220(b)(2)
Scientific justification for the validity of the hemodynamic indicator algorithm(s) must be provided.
Verification of algorithm calculations and validation testing of the algorithm must use an
independent data set.
Usability assessment must be provided to demonstrate that risk of misinterpretation of the status
indicator is appropriately mitigated.
Clinical data must support the intended use and include the following:
(i) The assessment must include a summary of the clinical data used, including source, patient
demographics, and any techniques used for annotating and separating the data;
(ii) Output measure(s) must be compared to an acceptable reference method to demonstrate that
the output represents the measure(s) that the device provides in an accurate and reproducible
manner;
(iii) The data set must be representative of the intended use population for the device. Any
selection criteria or limitations of the samples must be fully described and justified;
(iv) Where continuous measurement variables are displayed, agreement of the output with the
reference measure(s) must be assessed across the full measurement range; and
(v) Data must be provided within the clinical validation study or using equivalent datasets to
demonstrate the consistency of the output and be representative of the range of data sources
and data quality likely to be encountered in the intended use population and relevant use
conditions in the intended use environment.
Labeling must include the following:
(i) The type of sensor data used, including specification of compatible sensors for data
acquisition, and a clear description of what the device measures and outputs to the user;
(ii) Warnings identifying factors that may impact output results;
(iii) Guidance for interpretation of the outputs, including warning(s) specifying adjunctive use of the
measurements;
(iv) Key assumptions made in the calculation and determination of measurements; and
(v) A summary of the clinical validation data, including details of the patient population studied
(e.g., age, gender, race/ethnicity), clinical study protocols, and device performance with
confidence intervals for all intended use populations.
[87 FR 79254, Dec. 27, 2022]
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure
the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood
pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and
lower limits.
Classification. Class II (performance standards).
(5) (a) (b) 21 CFR 870.2300(b) (enhanced display) page 6 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2310
§ 870.2310 Apex cardiograph (vibrocardiograph).
(a) Identification. An apex cardiograph (vibrocardiograph) is a device used to amplify or condition the signal
from an apex cardiographic transducer and to produce a visual display of the motion of the heart; this
device also provides any excitation energy required by the transducer.
(b) Classification. Class II (performance standards).
§ 870.2320 Ballistocardiograph.
(a) Identification. A ballistocardiograph is a device, including a supporting structure on which the patient is
placed, that moves in response to blood ejection from the heart. The device often provides a visual
display.
(b) Classification. Class II (performance standards).
§ 870.2330 Echocardiograph.
(a) Identification. An echocardiograph is a device that uses ultrasonic energy to create images of
cardiovascular structures. It includes phased arrays and two-dimensional scanners.
(b) Classification. Class II (performance standards).
§ 870.2340 Electrocardiograph.
(a) Identification. An electrocardiograph is a device used to process the electrical signal transmitted through
two or more electrocardiograph electrodes and to produce a visual display of the electrical signal
produced by the heart.
(b) Classification. Class II (performance standards).
§ 870.2345 Electrocardiograph software for over-the-counter use.
(a) Identification. An electrocardiograph software device for over-the-counter use creates, analyzes, and
displays electrocardiograph data and can provide information for identifying cardiac arrhythmias. This
device is not intended to provide a diagnosis.
(b) Classification. Class II (special controls). The special controls for this device are:
(1) Clinical performance testing under anticipated conditions of use must demonstrate the following:
(i) The ability to obtain an electrocardiograph of sufficient quality for display and analysis; and
(ii) The performance characteristics of the detection algorithm as reported by sensitivity and either
specificity or positive predictive value.
(2) Software verification, validation, and hazard analysis must be performed. Documentation must
include a characterization of the technical specifications of the software, including the detection
algorithm and its inputs and outputs.
(3) Non-clinical performance testing must validate detection algorithm performance using a previously
adjudicated data set.
(4) Human factors and usability testing must demonstrate the following:
(i) The user can correctly use the device based solely on reading the device labeling; and
21 CFR 870.2345(b)(4)(i) (enhanced display) page 7 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2345(b)(4)(ii)
(ii) The user can correctly interpret the device output and understand when to seek medical care.
(5) Labeling must include:
(i) Hardware platform and operating system requirements;
(ii) Situations in which the device may not operate at an expected performance level;
(iii) A summary of the clinical performance testing conducted with the device;
(iv) A description of what the device measures and outputs to the user; and
(v) Guidance on interpretation of any results.
[86 FR 2549, Jan. 18, 2022]
§ 870.2350 Electrocardiograph lead switching adaptor.
(a) Identification. An electrocardiograph lead switching adaptor is a passive switching device to which
electrocardiograph limb and chest leads may be attached. This device is used to connect various
combinations of limb and chest leads to the output terminals in order to create standard lead
combinations such as leads I, II, and III.
(b) Classification. Class II (performance standards).
§ 870.2360 Electrocardiograph electrode.
(a) Identification. An electrocardiograph electrode is the electrical conductor which is applied to the surface
of the body to transmit the electrical signal at the body surface to a processor that produces an
electrocardiogram or vectorcardiogram.
Classification. Class II (special controls). The device is exempt from the premarket notification procedures
insubpart E of part 807 of this chaptersubject to the limitations in§ 870.9. The special control for this
(b) device is the FDA guidance document entitled “Class II Special Controls Guidance Document:
Electrocardiograph Electrodes.” See§ 870.1(e)for availability information of guidance documents.
[45 FR 7907, Feb. 5, 1980, as amended at 76 FR 43585, July 21, 2011]
§ 870.2370 Electrocardiograph surface electrode tester.
(a) Identification. An electrocardiograph surface electrode tester is a device used to test the function and
application of electrocardiograph electrodes.
(b) Classification. Class II (performance standards).
§ 870.2390 Phonocardiograph.
(a) Identification. A phonocardiograph is a device used to amplify or condition the signal from a heart sound
transducer. This device furnishes the excitation energy for the transducer and provides a visual or audible
display of the heart sounds.
(b) Classification. Class I (general controls). The device is exempt from the premarket notification procedures
insubpart E of part 807 of this chaptersubject to the limitations in§ 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 61 FR 1121, Jan. 16, 1996; 66 FR 38796, July 25, 2001]
21 CFR 870.2390(b) (enhanced display) page 8 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2400
§ 870.2400 Vectorcardiograph.
(a) Identification. A vectorcardiograph is a device used to process the electrical signal transmitted through
electrocardiograph electrodes and to produce a visual display of the magnitude and direction of the
electrical signal produced by the heart.
(b) Classification. Class II (performance standards).
§ 870.2450 Medical cathode-ray tube display.
(a) Identification. A medical cathode-ray tube display is a device designed primarily to display selected
biological signals. This device often incorporates special display features unique to a specific biological
signal.
(b) Classification. Class II (performance standards).
§ 870.2600 Signal isolation system.
(a) Identification. A signal isolation system is a device that electrically isolates the patient from equipment
connected to the commercial power supply received from a utility company. This isolation may be
accomplished, for example, by transformer coupling, acoustic coupling, or optical coupling.
(b) Classification. Class I (general controls). The device is exempt from the premarket notification procedures
insubpart E of part 807 of this chaptersubject to the limitations in§ 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 61 FR 1121, Jan. 16, 1996; 66 FR 38796, July 25, 2001]
§ 870.2620 Line isolation monitor.
(a) (b) Identification. A line isolation monitor is a device used to monitor the electrical leakage current from a
power supply electrically isolated from the commercial power supply received from a utility company.
Classification. Class I (general controls). The device is exempt from the premarket notification procedures
insubpart E of part 807 of this chaptersubject to the limitations in§ 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 61 FR 1121, Jan. 16, 1996; 66 FR 38796, July 25, 2001]
§ 870.2640 Portable leakage current alarm.
(a) (b) Identification. A portable leakage current alarm is a device used to measure the electrical leakage current
between any two points of an electrical system and to sound an alarm if the current exceeds a certain
threshold.
Classification. Class I (general controls). The device is exempt from the premarket notification procedures
insubpart E of part 807 of this chaptersubject to the limitations in§ 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 61 FR 1121, Jan. 16, 1996; 66 FR 38796, July 25, 2001]
§ 870.2675 Oscillometer.
(a) Identification. An oscillometer is a device used to measure physiological oscillations of any kind, e.g.,
changes in the volume of arteries.
21 CFR 870.2675(a) (enhanced display) page 9 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2675(b)
(b) Classification. Class II (special controls). The device is exempt from the premarket notification procedures
insubpart E of part 807 of this chaptersubject to the limitations in§ 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 84 FR 71812, Dec. 30, 2019]
§ 870.2700 Oximeter.
(a) Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood
and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It
may be used alone or in conjunction with a fiberoptic oximeter catheter.
(b) Classification. Class II (performance standards).
§ 870.2710 Ear oximeter.
(a) Identification. An ear oximeter is an extravascular device used to transmit light at a known wavelength(s)
through blood in the ear. The amount of reflected or scattered light as indicated by this device is used to
measure the blood oxygen saturation.
(b) Classification. Class II (performance standards).
§ 870.2750 Impedance phlebograph.
(a) Identification. An impedance phlebograph is a device used to provide a visual display of the venous pulse
or drainage by measuring electrical impedance changes in a region of the body.
(b) Classification. Class II (performance standards).
§ 870.2770 Impedance plethysmograph.
(a) Identification. An impedance plethysmograph is a device used to estimate peripheral blood flow by
measuring electrical impedance changes in a region of the body such as the arms and legs.
(b) Classification. Class II (special controls). The device, when it is a body composition analyzer which is not
intended to diagnose or treat any medical condition, is exempt from the premarket notification
procedures insubpart E of part 807 of this chaptersubject to the limitations in§ 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 84 FR 71812, Dec. 30, 2019]
§ 870.2780 Hydraulic, pneumatic, or photoelectric plethysmographs.
(a) Identification. A hydraulic, pneumatic, or photoelectric plethysmograph is a device used to estimate blood
flow in a region of the body using hydraulic, pneumatic, or photoelectric measurement techniques.
(b) Classification. Class II (performance standards).
§ 870.2785 Software for optical camera-based measurement of pulse rate, heart rate, breathing
rate, and/or respiratory rate.
(a) Identification. The device uses software algorithms to analyze video signal and estimate pulse rate, heart
rate, breathing rate, and/or respiratory rate. This device is not intended to independently direct therapy.
(b) Classification. Class II (special controls). The special controls for this device are:
21 CFR 870.2785(b) (enhanced display) page 10 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2785(b)(1)
(1) A software description and the results of verification and validation testing based on a
comprehensive hazard analysis and risk assessment must include:
(i) A full characterization of the software technical parameters, including algorithms;
(ii) If required image acquisition hardware is not included with the device, full specifications of the
hardware requirements and testing to demonstrate the specified hardware ensures adequate
data for validated and accurate measurements;
(iii) A description of the expected impact of all applicable sensor acquisition hardware
characteristics and associated hardware specifications;
(iv) A description of all mitigations for user error or failure of any subsystem components (including
signal detection, signal analysis, data display, and storage) on output accuracy; and
(v) Software documentation must include a cybersecurity vulnerability and management process
to assure software functionality.
(2) Clinical data must be provided. This assessment must fulfill the following:
(i) The clinical data must be representative of the intended use population for the device. Any
selection criteria or sample limitations must be fully described and justified.
(ii) The assessment must demonstrate output consistency using the expected range of data
sources and data quality encountered in the intended use population and environment.
(iii) The assessment must compare device output with a clinically accurate patient-contacting
relevant comparator device in an accurate and reproducible manner.
(3) A human factors and usability engineering assessment must be provided that evaluates the risk of
improper measurement.
(4) Labeling must include:
(i) A description of what the device measures and outputs to the user;
(ii) Warnings identifying sensor acquisition factors or subject conditions or characteristics
(garment types/textures, motion, etc.) that may impact measurement results;
(iii) Guidance for interpretation of the measurements, including a statement that the output is
adjunctive to other physical vital sign parameters and patient information;
(iv) The expected performance of the device for all intended use populations and environments;
and
(v) Robust instructions to ensure correct system setup.
[88 CFR 6167, Jan. 31, 2023]
§ 870.2786 Hardware and software for optical camera-based measurement of pulse rate, heart
rate, breathing rate, and/or respiratory rate.
(a) Identification. The device uses an optical sensor system and software algorithms to obtain and analyze
video signal and estimate pulse rate, heart rate, breathing rate, and/or respiratory rates. This device is not
intended to independently direct therapy.
21 CFR 870.2786(a) (enhanced display) page 11 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2786(b)
(b) Classification. Class II (special controls). The special controls for this device are:
(1) A software description and the results of verification and validation testing based on a
comprehensive hazard analysis and risk assessment must include:
(i) A full characterization of the software technical parameters, including algorithms;
(ii) A description of all mitigations for user error or failure of any subsystem components (including
signal detection, signal analysis, data display, and storage) on output accuracy; and
(iii) Software documentation must include a cybersecurity vulnerability and management process
to assure software functionality.
(2) Performance testing must demonstrate the safety of any illuminating optics.
(3) Clinical data must be provided. This assessment must fulfill the following:
(i) The clinical data must be representative of the intended use population for the device. Any
selection criteria or sample limitations must be fully described and justified.
(ii) The assessment must demonstrate output consistency using the expected range of data
sources and data quality encountered in the intended use population and environment.
(iii) The assessment must compare device output with a clinically accurate patient-contacting
relevant comparator device in an accurate and reproducible manner.
(4) A human factors and usability engineering assessment must be provided that evaluates the risk of
improper measurement.
(5) Labeling must include:
(i) A description of what the device measures and outputs to the user;
(ii) Warnings identifying sensor acquisition factors or subject conditions or characteristics
(garment types/textures, motion, etc.) that may impact measurement results;
(iii) Guidance for interpretation of the measurements, including a statement that the output is
adjunctive to other physical vital sign parameters and patient information;
(iv) The expected performance of the device for all intended use populations and environments;
and
(v) Robust instructions to ensure correct system setup.
[88 FR 976, Jan. 6, 2023]
§ 870.2790 Photoplethysmograph analysis software for over-the-counter use.
Identification. A photoplethysmograph analysis software device for over-the-counter use analyzes
photoplethysmograph data and provides information for identifying irregular heart rhythms. This device is
not intended to provide a diagnosis.
Classification. Class II (special controls). The special controls for this device are:
(1) Clinical performance testing must demonstrate the performance characteristics of the detection
algorithm under anticipated conditions of use.
21 CFR 870.2790(b)(1) (enhanced display) page 12 of 15
(a) (b) 
(2) (3) (4) 21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2790(b)(2)
Software verification, validation, and hazard analysis must be performed. Documentation must
include a characterization of the technical specifications of the software, including the detection
algorithm and its inputs and outputs.
Non-clinical performance testing must demonstrate the ability of the device to detect adequate
photoplethysmograph signal quality.
Human factors and usability testing must demonstrate the following:
(i) The user can correctly use the device based solely on reading the device labeling; and
(ii) The user can correctly interpret the device output and understand when to seek medical care.
(5) Labeling must include:
(i) Hardware platform and operating system requirements;
(ii) Situations in which the device may not operate at an expected performance level;
(iii) A summary of the clinical performance testing conducted with the device;
(iv) A description of what the device measures and outputs to the user; and
(v) Guidance on interpretation of any results.
[87 FR 6419, Feb. 4, 2022]
§ 870.2800 Medical magnetic tape recorder.
(a) Identification. A medical magnetic tape recorder is a device used to record and play back signals from, for
example, physiological amplifiers, signal conditioners, or computers.
Classification. Class II (performance standards).
§ 870.2810 Paper chart recorder.
Identification. A paper chart recorder is a device used to print on paper, and create a permanent record of
the signal from, for example, a physiological amplifier, signal conditioner, or computer.
Classification. Class I (general controls). The device is exempt from the premarket notification procedures
insubpart E of part 807 of this chaptersubject to the limitations in§ 870.9.
(b) (a) (b) [45 FR 7907, Feb. 5, 1980, as amended at 61 FR 1121, Jan. 16, 1996; 66 FR 38796, July 25, 2001]
§ 870.2840 Apex cardiographic transducer.
(a) (b) Identification. An apex cardiographic transducer is a device used to detect motion of the heart
(acceleration, velocity, or displacement) by changes in the mechanical or electrical properties of the
device.
Classification. Class II (performance standards).
21 CFR 870.2840(b) (enhanced display) page 13 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2850
§ 870.2850 Extravascular blood pressure transducer.
(a) Identification. An extravascular blood pressure transducer is a device used to measure blood pressure by
changes in the mechanical or electrical properties of the device. The proximal end of the transducer is
connected to a pressure monitor that produces an analog or digital electrical signal related to the
electrical or mechanical changes produced in the transducer.
(b) Classification. Class II (performance standards).
§ 870.2855 Implantable Intra-aneurysm Pressure Measurement System.
(a) Identification. Implantable intra-aneurysm pressure measurement system is a device used to measure the
intra-sac pressure in a vascular aneurysm. The device consists of a pressure transducer that is implanted
into the aneurysm and a monitor that reads the pressure from the transducer.
(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II
Special Controls Guidance Document: Implantable Intra-Aneurysm Pressure Measurement System.” See§
870.1 (e)for the availability of this guidance document.
[71 FR 7871, Feb. 15, 2006]
§ 870.2860 Heart sound transducer.
(a) Identification. A heart sound transducer is an external transducer that exhibits a change in mechanical or
electrical properties in relation to sounds produced by the heart. This device may be used in conjunction
with a phonocardiograph to record heart sounds.
(b) Classification. Class II (performance standards).
§ 870.2870 Catheter tip pressure transducer.
(a) Identification. A catheter tip pressure transducer is a device incorporated into the distal end of a catheter.
When placed in the bloodstream, its mechanical or electrical properties change in relation to changes in
blood pressure. These changes are transmitted to accessory equipment for processing.
(b) Classification. Class II (performance standards).
§ 870.2880 Ultrasonic transducer.
(a) Identification. An ultrasonic transducer is a device applied to the skin to transmit and receive ultrasonic
energy that is used in conjunction with an echocardiograph to provide imaging of cardiovascular
structures. This device includes phased arrays and two-dimensional scanning transducers.
(b) Classification. Class II (performance standards).
§ 870.2890 Vessel occlusion transducer.
(a) Identification. A vessel occlusion transducer is a device used to provide an electrical signal corresponding
to sounds produced in a partially occluded vessel. This device includes motion, sound, and ultrasonic
transducers.
(b) Classification. Class II (performance standards).
21 CFR 870.2890(b) (enhanced display) page 14 of 15
21 CFR Part 870 Subpart C (up to date as of 5/22/2025)
Cardiovascular Monitoring Devices
21 CFR 870.2900
§ 870.2900 Patient transducer and electrode cable (including connector).
(a) Identification. A patient transducer and electrode cable (including connector) is an electrical conductor
used to transmit signals from, or power or excitation signals to, patient-connected electrodes or
transducers.
(b) Classification. Class II (performance standards).
§ 870.2910 Radiofrequency physiological signal transmitter and receiver.
(a) Identification. A radiofrequency physiological signal transmitter and receiver is a device used to condition
a physiological signal so that it can be transmitted via radiofrequency from one location to another, e.g., a
central monitoring station. The received signal is reconditioned by the device into its original format so
that it can be displayed.
(b) Classification. Class II (performance standards).
§ 870.2920 Telephone electrocardiograph transmitter and receiver.
(a) Identification. A telephone electrocardiograph transmitter and receiver is a device used to condition an
electrocardiograph signal so that it can be transmitted via a telephone line to another location. This
device also includes a receiver that reconditions the received signal into its original format so that it can
be displayed. The device includes devices used to transmit and receive pacemaker signals.
(b) Classification. Class II (performance standards).
21 CFR 870.2920(b) (enhanced display) page 15 of 15